Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer
Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer
复制标题
DOI：
10.21037/atm.2020.03.16
复制
发表时间：
2020-03
影响因子：
--
通讯作者：
J. Wall;R. Arend
中科院分区：
文献类型：
--
作者：
J. Wall;R. Arend
美国阿拉巴马大学伯明翰分校妇产科肿瘤科通讯：丽贝卡·C·阿伦德医学博士阿拉巴马大学伯明翰分校，美国亚利桑那州伯明翰19街南619号，10250室176楼。电子邮件：rarend@uabmc.edu。来源与同行评审：本文由执行主编胡志德博士(内蒙古医科大学附属医院检验医学科，呼和浩特，中国)委托评审。评论：Moore KN，Gunderson CC，SabBatini P等人复发性铂敏感卵巢癌患者联合紫杉醇和卡铂的1b期剂量递增研究。《妇科在线》2019；154：294-301。
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, USA Correspondence to: Rebecca C. Arend, MD. University of Alabama at Birmingham, 619 19 Street South, 176F Room 10250, Birmingham, AL, USA. Email: rarend@uabmc.edu. Provenance and Peer Review: This article was commissioned and reviewed by the Executive Editor Dr. Zhi-De Hu (Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China). Comment on: Moore KN, Gunderson CC, Sabbatini P, et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 2019;154:294-301.